A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 17 Mar 2010
At a glance
- Drugs Digoxin; Latrepirdine
- Indications Alzheimer's disease; Atrial fibrillation; Heart failure; Huntington's disease
- Focus Pharmacokinetics
- Sponsors Pfizer
- 17 Mar 2010 Results have been presented at the 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 16 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Apr 2009 Additional location identified as reported by ClinicalTrials.gov.